Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab every-4-weeks regimen in primary hypercholesterolemia
2013-002343-29Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing Alirocumab with Placebo (2 arms). Primary endpoint: Percent change in calculated LDL-C from baseline to week 24 in the ITT population. Started Jul 2013; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2013-002343-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002343-29.